drugset / Trial / NCT00695305
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A study in patients with atherosclerosis to assess safety, effect and PK of rilapladib vs. placebo over 12 weeks of dosing.
Timeline
- Start
- 2008-11
- Primary completion
- 2010-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rilapladib | Small molecule | 250 mg | Oral |